Binds Expression Product Or Fragment Thereof Of Cancer-related Gene (e.g., Oncogene, Proto-oncogene, Etc.) Patents (Class 424/138.1)
  • Immunological compositions as cancer biomarkers and/or therapeutics
    Patent number: 8501417
    Abstract: The present invention concerns antibodies that react immunologically with anti-tumor antigen antibodies and compositions and methods related thereto. In particular, the antibodies that react immunologically with the anti-tumor antigen antibodies are employed in therapeutic, diagnostic, and prognostic embodiments related to cancer, including breast cancer, for example.
    Type: Grant
    Filed: June 26, 2008
    Date of Patent: August 6, 2013
    Assignee: Vanderbilt University
    Inventors: Paula R. Pohlmann, Ray Mernaugh, Carlos Arteaga
  • Immunological compositions as cancer therapeutics
    Patent number: 8486413
    Abstract: The present invention concerns antibodies that react immunologically with an epitope comprising VDKSRWQQG (SEQ ID NO: 1), including those that bind to cancer cells, and methods relating thereto. In particular, the antibodies that react immunologically with a particular epitope found in anti-tumor antigen antibodies are not only indicative of favorable therapy using the anti-tumor antigen antibodies, but are therapeutic in and of themselves.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: July 16, 2013
    Assignee: Vanderbilt University
    Inventors: Paula R. Pohlmann, Raymond L. Mernaugh, Carlos L. Arteaga
  • Methods of inhibiting unwanted cell proliferation using an antibody that binds to sonic hedgehog and inhibits hedgehog signaling
    Patent number: 8486400
    Abstract: The present application is directed to compositions and methods for inhibiting angiogenesis and treating or preventing unwanted cell proliferation, including tumors, by inhibiting the hedgehog pathway, e.g., with an antagonist of the hedgehog pathway such as those disclosed herein.
    Type: Grant
    Filed: June 1, 2010
    Date of Patent: July 16, 2013
    Assignee: Curis, Inc.
    Inventors: Henryk Dudek, Irina Karavanov, Carmen Pepicelli
  • Alpha-emitting constructs and uses thereof
    Patent number: 8486409
    Abstract: The present invention discloses alpha particle emitting, radioactive constructs capable of killing large tumors (>1 mm in diameter), or other cells involved in human or animal diseases such as virus infected cells, autoimmune cells, or other pathological cells, including normal cells, that are targets for destruction, to achieve a therapeutic result. The alpha-emitting constructs have high specific activity.
    Type: Grant
    Filed: April 20, 2010
    Date of Patent: July 16, 2013
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: David A. Scheinberg, Michael R. McDevitt, Dangshe Ma, George Sgouros
  • Combination therapies comprising quinoxaline inhibitors of P13K-alpha for use in the treatment of cancer
    Patent number: 8481001
    Abstract: The present invention provides methods of treating cancer by administering a compound of Formula I, optionally as a pharmaceutically acceptable salt, solvate and/or hydrate thereof, in combination with other cancer treatments.
    Type: Grant
    Filed: April 8, 2008
    Date of Patent: July 9, 2013
    Assignee: Exelixis, Inc.
    Inventors: Peter Lamb, David Matthews
  • Human antibodies that bind CD22 and uses thereof
    Patent number: 8481683
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.
    Type: Grant
    Filed: November 30, 2007
    Date of Patent: July 9, 2013
    Assignee: Medarex, Inc.
    Inventors: David John King, Alison Witte, Heidi N. LeBlanc, Richard Theolis, Asna Masood, Mark Yamanaka, Kyra D. Zens, Sarah R. Reed, Tim Sproul, Chetana Rao-Naik, David Passmore, Dawn M. Tanamachi, Kristopher Toy
  • Therapeutic agent for cancer, and method for treatment of cancer
    Patent number: 8481497
    Abstract: [PROBLEMS] To provide a technique which enables an effective antibody therapy for cancer which targets for FGFR1 without the need of using any effective antibody having high specificity and a potent cell-killing activity. [MEANS FOR SOLVING PROBLEMS] Disclosed are: a therapeutic agent for cancer, which comprises an enhancer of the expression of a fibroblast growth factor receptor-1 and an anti-fibroblast growth factor receptor-1 antibody; and a method for the treatment of cancer using the therapeutic agent.
    Type: Grant
    Filed: May 29, 2008
    Date of Patent: July 9, 2013
    Assignees: Sapporo Medical University, The University of Tokyo
    Inventors: Kohzoh Imai, Shigeru Sasaki, Tsutomu Seito
  • MONOCLONAL ANTIBODIES AGAINST HER2 EPITOPE
    Publication number: 20130171148
    Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Application
    Filed: May 27, 2011
    Publication date: July 4, 2013
    Applicant: GENMAB A/S
    Inventors: Bart De Goeij, Edward Norbert Van Den Brink, Simone De Haij, Thilo Riedl, Rene Hoet, Ole Baadsgaard, David Satijn, Jan Van De Winkel, Paul Parren
  • Bispecific anti-IGF-1R and anti-ErbB3 antibodies
    Patent number: 8476409
    Abstract: Provided are bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3.
    Type: Grant
    Filed: April 19, 2012
    Date of Patent: July 2, 2013
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Jason Baum, Bryan Johnson, Alexey Alexandrovich Lugovskoy, Lihui Xu, Neeraj Kohli, Jonathan Basil Fitzgerald, Sharlene Adams
  • PSMA antibodies and uses thereof
    Patent number: 8470330
    Abstract: The invention includes stable multimeric, particularly dimeric, forms of PSMA protein, compositions and kits containing dimeric PSMA protein as well as methods of producing, purifying and using these compositions. Such methods include methods for eliciting or enhancing an immune response to cells expressing PSMA, including methods of producing antibodies to dimeric PSMA, as well as methods of treating cancer, such as prostate cancer.
    Type: Grant
    Filed: July 28, 2010
    Date of Patent: June 25, 2013
    Assignees: PSMA Development Company, LLC, Amgen Fremont Inc.
    Inventors: Paul J. Maddon, Gerald P. Donovan, William C. Olson, Norbert Schuelke, Jason Gardner, Dangshe Ma, Jaspal S. Kang, Larry Green
  • Monoclonal antibody therapy for pancreas cancer
    Patent number: 8470326
    Abstract: The present invention relates to the use of binding equivalents of monoclonal antibody 31.1, including chimerized and/or humanized versions thereof, antibody fragments as well as competitively binding and co-specific antibodies and antibody fragments, in the treatment of pancreatic cancer.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: June 25, 2013
    Assignee: Precision Biologics
    Inventors: Myron Arlen, Kwong Tsang
  • Down-regulation of mortalin by siRNA
    Patent number: 8470793
    Abstract: Use of a siRNA molecule selected from the group consisting of SEQ ID NO: 173 to 344 for treating a disease associated with a pathological cell population in a subject in need thereof is disclosed. Pharmaceutical compositions and articles of manufacture comprising the siRNAs are also disclosed.
    Type: Grant
    Filed: September 25, 2008
    Date of Patent: June 25, 2013
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Zvi Fishelson, David Pilzer
  • Antibody Therapy
    Publication number: 20130156691
    Abstract: The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition.
    Type: Application
    Filed: May 21, 2012
    Publication date: June 20, 2013
    Applicant: IMMUNOMEDICS, INC.
    Inventors: David M. Goldenberg, Hans J. Hansen
  • NEUTRALIZATION OF FLT3 LIGAND AS A LEUKEMIA THERAPY
    Publication number: 20130156764
    Abstract: Disclosed herein are methods and compositions for treating leukemia and preventing leukemia relapse related to the administration of agents that inhibit the binding of FLT3 ligand to FLT3.
    Type: Application
    Filed: March 14, 2011
    Publication date: June 20, 2013
    Applicant: The Johns Hopkins University
    Inventors: Mark J. Levis, Donald Small
  • DOSAGES FOR TREATMENT WITH ANTI-EGFR ANTIBODIES
    Publication number: 20130149299
    Abstract: The present invention concerns dosages for treatment of human cancer patients with an anti-Epidermal Growth Factor Receptor (EGFR) antibody.
    Type: Application
    Filed: March 8, 2012
    Publication date: June 13, 2013
    Inventors: Sharon A. Baughman, Steven Shak
  • Antibodies
    Patent number: 8461304
    Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.
    Type: Grant
    Filed: June 9, 2010
    Date of Patent: June 11, 2013
    Assignee: Affitech Research AS
    Inventors: Lavinia Diana Cicortas Gunnarsson, Didrik Paus
  • Therapeutic use of anti-CS1 antibodies
    Patent number: 8461306
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: June 11, 2013
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, David B. Powers, Gao Liu
  • COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER
    Publication number: 20130142730
    Abstract: The present invention provides organic arsenicals. Many of these compounds have potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia.
    Type: Application
    Filed: November 14, 2012
    Publication date: June 6, 2013
    Applicant: ZIOPHARM ONCOLOGY, INC.
    Inventor: ZIOPHARM Oncology, Inc.
  • Methods for detecting and inhibiting angiogenesis
    Patent number: 8454958
    Abstract: The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting ?5?1 integrin in the tissue with an agent that interferes with specific binding of the ?5?1 integrin to a ligand expressed in the tissue. The invention further provides methods of reducing or inhibiting angiogenesis in a tissue in an individual, by administering to the individual an agent that interferes with the specific binding of ?5?1 integrin to a ligand expressed in the tissue; and methods of reducing the severity of a pathological condition associated with angiogenesis in an individual, by administering to the individual an agent that interferes with specific binding of ?5?1 integrin to a ligand in a tissue associated with the pathological condition.
    Type: Grant
    Filed: December 7, 2011
    Date of Patent: June 4, 2013
    Assignee: The Regents of the University of California
    Inventor: Judith A. Varner
  • Compositions and methods for diagnosing and treating cancer
    Patent number: 8455623
    Abstract: Isolated antibodies that specifically bind the human MET Receptor and inhibit MET signaling are described. Also described are methods of treating cancer, the methods comprising administering a therapeutically effective amount of the provided MET antibodies and combinations thereof.
    Type: Grant
    Filed: May 21, 2009
    Date of Patent: June 4, 2013
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Edward Thein Htun Van Der Horst, Aaron Ken Sato
  • Anti-VEGF antibodies
    Patent number: 8449885
    Abstract: The vascular endothelial growth factor (VEGF) activity in a patient's bloodstream or other biological sample can serve as a diagnostic and prognostic index for cancer, diabetes, heart conditions, and other pathologies. Antibody-sandwich ELISA methods and kits for VEGF as an antigen are provided to detect types of VEGF levels in biological samples from animal models and human patients and can be used as a diagnostic/prognostic index.
    Type: Grant
    Filed: June 17, 2010
    Date of Patent: May 28, 2013
    Assignee: Genentech, Inc.
    Inventors: Yu-Ju G. Meng, Kyu H. Hong, Johnny Gutierrez
  • COMPOSITION AND METHODS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF LEUKEMIA
    Publication number: 20130129734
    Abstract: The present disclosure relates generally to compositions and methods for the diagnosis, prognosis and treatment of leukemia, in particular leukemia in which leukemic cells, or neoplastic precursors thereof, express Fat1 or a homolog of Fat1 that is substantially not expressed on normal blood cells.
    Type: Application
    Filed: November 13, 2012
    Publication date: May 23, 2013
    Applicant: NEWCASTLE INNOVATION LIMITED
    Inventor: Newcastle Innovation Limited
  • ANTI C-MET ANTIBODY AND USES THEREOF
    Publication number: 20130129731
    Abstract: An anti c-Met antibody or antigen-binding fragment thereof comprising a heavy-chain variable region having heavy-chain complementarity determining region (CDR) amino acid sequences of SEQ ID NOs: 1, 2 and 3, and a light-chain variable region having light-chain CDR amino acid sequences of SEQ ID NOs: 4, 5, and 6; and a method of wound healing, tissue regeneration, or cell proliferation comprising administration of same; as well as related compositions and methods.
    Type: Application
    Filed: November 16, 2012
    Publication date: May 23, 2013
    Applicant: SAMSUNG ELECTRONICS CO., LTD.
    Inventor: Samsung Electronics Co., Ltd.
  • PURIFICATION OF ANTI-C-MET ANTIBODIES
    Publication number: 20130129718
    Abstract: Provided herein are methods of purifying anti-c-met antibodies, compositions and pharmaceutical formulations comprising purified anti-c-met antibodies, and methods of using the same.
    Type: Application
    Filed: November 20, 2012
    Publication date: May 23, 2013
    Applicant: GENENTECH, INC.
    Inventor: Genentech, Inc.
  • Antitumor antibodies, proteins, and uses thereof
    Patent number: 8444972
    Abstract: Antibodies that bind to a 40 kDa protein which is expressed on tumors, but is not expressed on normal adult hemopoietic cells are disclosed. Also disclosed are methods for production and the use of such antibodies.
    Type: Grant
    Filed: August 5, 2010
    Date of Patent: May 21, 2013
    Assignee: University of Massachusetts
    Inventors: Kenneth L. Rock, Dancella Fernandes
  • Compositions and methods for diagnosing, treating, and preventing prostate conditions
    Patent number: 8445444
    Abstract: Disclosed are compositions and methods for diagnosing, preventing, and treating prostate cancer and prostate intraepithelial neoplasia (PIN).
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: May 21, 2013
    Assignee: Phigenix, Inc.
    Inventor: Carlton D. Donald
  • METHODS OF INHIBITING TUMOR GROWTH BY ANTAGONIZING IL-6 RECEPTOR
    Publication number: 20130122003
    Abstract: The present invention provides methods for inhibiting or attenuating tumor growth in a subject by administering an IL-6 antagonist to the subject. In certain embodiments, the methods of the invention are used to inhibit the growth of an anti-VEGF-resistant tumor in a subject. The IL-6 antagonist may be, e.g., an antibody that specifically binds IL-6R. The IL-6 antagonist may be administered in combination with a VEGF antagonist, and/or an EGFR antagonist.
    Type: Application
    Filed: November 9, 2012
    Publication date: May 16, 2013
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventor: Regeneron Pharmaceuticals, Inc.
  • Bispecific binding agents for modulating biological activity
    Patent number: 8440192
    Abstract: Methods for improving the biological and pharmaceutical properties of bispecific binding agents are described herein where the bispecific binding agents are able to target cells by a high affinity binding domain to a first cell surface marker that does not induce a significant biological effect and a low affinity binding domain that binds specifically to a second cell surface marker, causing a significant and desired biological effect. Compositions of such bispecific binding agents, uses for them, and kits containing them are also provided.
    Type: Grant
    Filed: January 18, 2012
    Date of Patent: May 14, 2013
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Ulrik B. Nielsen, Birgit M. Schoeberl
  • Anti-hepsin antibodies and methods using same
    Patent number: 8435511
    Abstract: The invention provides hepsin antibodies, and compositions comprising and methods of using these antibodies.
    Type: Grant
    Filed: October 21, 2010
    Date of Patent: May 7, 2013
    Assignee: Genentech, Inc.
    Inventors: Rajkumar Ganesan, Daniel Kirchhofer, Paul M. Moran, Yingnan Zhang
  • Therapeutic use of anti-CS1 antibodies
    Patent number: 8436146
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: May 7, 2013
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, David B. Powers, Gao Liu
  • METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY-MAYTANSINOID CONJUGATES
    Publication number: 20130108620
    Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.
    Type: Application
    Filed: November 28, 2011
    Publication date: May 2, 2013
    Applicants: GENENTECH, INC., IMMUNOGEN INC.
    Inventors: Walter BLATTLER, Ravi V.J. CHARI, Mark SLIWKOWSKI, Sharon ERICKSON, Gail Colbern Schwall
  • Methods of treatment by administering antibodies to notch receptors
    Patent number: 8425903
    Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: April 23, 2013
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
  • Treatment with anti-ErbB2 antibodies
    Patent number: 8425908
    Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin. The invention further provides a method of treating cancer in a human patient comprising administering effective amounts of an anti-ErbB2 antibody and a cardioprotectant to the patient.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: April 23, 2013
    Assignee: Genentech, Inc.
    Inventor: Susan D. Hellmann
  • Method to inhibit cancer targeting CD24
    Patent number: 8425906
    Abstract: The present invention relates to a method to inhibit cancer by targeting CD24, more precisely a method to inhibit cancer by using CD24 expressed in most cancer cells as a target of an antibody therapeutic agent or by inhibiting the interaction between CD24 and P-selectin. CD24 is over-expressed in most cancer cells and CD24 accumulated in cytoplasm accelerates metastasis. Therefore, the method to inhibit cancer of the invention by targeting CD24 can be effectively used for the treatment of cancer by inhibiting the progress of various cancers over-expressing CD24.
    Type: Grant
    Filed: July 2, 2007
    Date of Patent: April 23, 2013
    Assignee: SNU R&DB Foundation
    Inventors: Young Kee Shin, Yoon-La Choi, Young Woo Park, Seung Hyun Lee, Kyoung Song
  • Methods and compositions for modulating tumor cell activity
    Patent number: 8426562
    Abstract: Antibodies which target clusterin, a protein involved in the epithelial-to-mesenchymal transition of carcinoma cells, are identified and characterized. The antibodies may be used to modulate tumor cell activity through binding the clusterin.
    Type: Grant
    Filed: July 29, 2010
    Date of Patent: April 23, 2013
    Assignee: National Research Council of Canada
    Inventors: Maureen D. O'Connor-McCourt, Christiane Cantin, Anne E. G. Lenferink
  • Fully human antibodies specific to CADM1
    Patent number: 8420084
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, more particularly engineered antibodies resulting in increased binding to Fc receptors and/or increased potency for ADCC or immunoconjugates, which specifically bind to CADM1 with high affinity. Nucleic acid molecules encoding CADM1 antibodies, expression vectors, host cells and methods for expressing the CADM1 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the CADM1 antibodies are also provided. Methods for detecting CADM1, as well as methods for treating various cancers, including lung cancer and pancreatic cancer, are disclosed.
    Type: Grant
    Filed: March 5, 2010
    Date of Patent: April 16, 2013
    Assignees: Medarex, Inc., Oxford BioTherapeutics Ltd
    Inventors: Jonathan Alexander Terrett, Heidi Leblanc, Haichun Huang, Erika Meaddough, Chin Pan, Bingliang Chen, Chetana Rao-Naik
  • Antibodies Directed to ERBB2
    Publication number: 20130089544
    Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to ErbB2, preferably human ErbB2. In another embodiment, the antibodies or antigen-binding portions thereof inhibit ErbB2. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins or portions thereof derived from human anti-ErbB2 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-ErbB2 antibodies.
    Type: Application
    Filed: December 11, 2012
    Publication date: April 11, 2013
    Applicant: MedImmune Limited
    Inventor: MedImmune Limited
  • ANTI C-MET ANTIBODY AND USES THEREOF
    Publication number: 20130089542
    Abstract: An anti c-Met antibody or antibody fragment and pharmaceutical composition comprising same, as well as a method for preventing and treating cancer by administering the antibody to a subject.
    Type: Application
    Filed: October 5, 2012
    Publication date: April 11, 2013
    Applicant: SAMSUNG ELECTRONICS CO., LTD.
    Inventor: Samsung Electronics Co. Ltd.
  • TUMOR TARGETED ANTIBODIES AND METHOD FOR USING THE SAME
    Publication number: 20130089496
    Abstract: Isolated and recombinant antibodies, such as EGFR-binding antibodies. Antibodies can comprising the sequence of an immunoglobulin heavy constant gamma-1 region encoded by a human G1M3 allele. For example, antibodies of the embodiments can comprise an immunoglobulin heavy constant gamma-1 region wherein position 214 is arginine; position 356 is glutamic acid; position 358 is methionine and/or position 431 is alanine. Methods for treating diseases, such as cancer, in a human subject with such antibodies are also provided.
    Type: Application
    Filed: October 5, 2012
    Publication date: April 11, 2013
    Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
    Inventor: Musc Foundation For Research Development
  • ANTI C-MET HUMANIZED ANTIBODY AND USES THEREOF
    Publication number: 20130089556
    Abstract: An anti c-Met antibody, a composition comprising the antibody, and a method for preventing or treating cancer by administering the composition is provided.
    Type: Application
    Filed: August 20, 2012
    Publication date: April 11, 2013
    Applicant: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Kwang Ho CHEONG, Seunghyun LEE, Geun Woong KIM, Kyung-Ah KIM, Young Mi OH, Saet Byoul LEE, Soo-yeon JUNG, Yunju JEONG, Young Kue HAN
  • ANTIBODY SPECIFICALLY BINDING TO EPITOPE IN SEMA DOMAIN OF C-MET
    Publication number: 20130089557
    Abstract: An antibody or antigen binding fragment thereof that specifically binds to an epitope in a SEMA domain of c-Met protein, and pharmaceutical compositions, methods, kits, nucleic acids, and cells related thereto.
    Type: Application
    Filed: October 5, 2012
    Publication date: April 11, 2013
    Applicant: SAMSUNG ELECTRONICS CO., LTD.
    Inventor: Samsung Electronics Co., Ltd.
  • Human antibodies to human RANKL, encoding nucleic acids and methods of treatment
    Patent number: 8414890
    Abstract: Isolated human antibodies or antigen-binding fragments thereof, which specifically bind to human RANKL and block hRANKL binding to a RANK receptor, are provided. The antibodies are useful in preventing or treating disorders and/or diseases, which are associated with RANKL/RANK interactions, including bone disorders or cancer.
    Type: Grant
    Filed: August 19, 2009
    Date of Patent: April 9, 2013
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Joel H. Martin, Aris N. Economides, Regina Raz
  • Recombinant anti-epidermal growth factor receptor antibody compositions
    Patent number: 8414896
    Abstract: The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides compositions or mixtures of antibodies capable of binding human EGFR. Antibody compositions with 3 or more antibodies showed synergy in reduction of proliferation of representative cancer cell lines. Advantageous results have also been obtained with a composition comprising two different chimeric anti-hEGFR antibodies which show a new mechanism of action based on rapid and efficient receptor internalisation, induction of terminal differentiation and subsequent tumour eradication in an animal model. The antibodies of the invention can be manufactured in one bioreactor as a polyclonal antibody.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: April 9, 2013
    Assignee: Symphogen A/S
    Inventors: Mikkel Wandahl Pedersen, Lucilla Steinaa, Allan Jensen, Klaus Koefoed, Per-Johan Meijer, Robert Carlsson, Charles Pyke, Lars Sogaard Nielsen
  • Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
    Patent number: 8409573
    Abstract: The present invention provides novel anti-CD71 monoclonal antibodies, in particular mouse-human chimeric anti-CD71 monoclonal antibodies, advantageously associated to effector cells for triggering ADCC mechanisms. Anti-CD71 antibodies, as well as pharmaceutical compositions containing them, are useful for inhibiting proliferation and/or killing malignant tumour cells, especially metastatic cutaneous and uveal melanoma cells.
    Type: Grant
    Filed: June 14, 2006
    Date of Patent: April 2, 2013
    Assignees: Mablife, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Laurence Boumsell, Jean Kadouche, Armand Bensussan
  • COMBINATION TREATMENTS COMPRISING C-MET ANTAGONISTS AND B-RAF ANTAGONISTS
    Publication number: 20130078252
    Abstract: The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to therapies for the treatment of pathological conditions, such as cancer.
    Type: Application
    Filed: September 19, 2012
    Publication date: March 28, 2013
    Applicant: GENENTECH, INC.
    Inventor: Genentech, Inc.
  • Neutralizing monoclonal antibody against human DLL4
    Patent number: 8404233
    Abstract: The present invention provides a binding protein capable of binding to delta-like ligand 4 (DLL4) as well as methods and uses thereof in therapy, diagnosis or imaging. Also provided are fusion proteins and protein conjugates, nucleic acid molecules encoding the binding proteins and methods of preparing binding proteins capable of binding to DLL4.
    Type: Grant
    Filed: May 15, 2008
    Date of Patent: March 26, 2013
    Assignee: Smart Targeting Limited
    Inventors: Makoto Sunamura, Hideo Yagita
  • Anti-Notch2 NRR antibodies
    Patent number: 8404239
    Abstract: The invention provides anti-Notch antibodies, and in particular, antibodies that bind Notch2 NRR, and methods of using the same.
    Type: Grant
    Filed: September 30, 2009
    Date of Patent: March 26, 2013
    Assignee: Genentech, Inc.
    Inventors: Christian W. Siebel, Yan Wu
  • Fixed dosing of HER antibodies
    Patent number: 8404234
    Abstract: The present invention concerns fixed dosing of HER antibodies, such as Pertuzumab.
    Type: Grant
    Filed: October 9, 2008
    Date of Patent: March 26, 2013
    Assignee: Genentech, Inc.
    Inventors: David E. Allison, Rene Bruno, Jian-Feng Lu, Chee M. Ng
  • ANTAGONISTS OF PRODUCTS OF THE HS.459642 UNIGENE CLUSTER FOR THE INHIBITION OF PROLIFERATION, DEVELOPMENT OR DIFFERENTIATION OF STEM CELLS INCLUDING CANCER STEM CELLS
    Publication number: 20130064814
    Abstract: The present disclosure provides methods and compositions for inhibiting the proliferation, differentiation, or development of stem cells and cancer stem cells in a patient in need thereof. The methods involve administering to a patient a therapeutically effective amount of an antagonist of an Hs.459642 Unigene Cluster product, such as an inhibitor of CACNA1H. The compositions include an antagonist of an Hs.459642 Unigene Cluster product, such as an inhibitor of CACNA1H. Specific antagonists such as antibodies and antisense oligonucleotides, and combination therapy with one or more additional anti-cancer agents, are also provided by this disclosure. Such methods, antagonists, and compositions can be useful, for example, in the treatment of cancer.
    Type: Application
    Filed: September 11, 2012
    Publication date: March 14, 2013
    Inventor: Lloyd S. Gray
  • Pharmaceutical compositions with resistance to soluble CEA
    Patent number: 8394926
    Abstract: The present disclosure relates to a bispecific single chain antibody which has a first binding domain specifically binding to human CD3, and a second binding domain specifically binding to human CEA, where the second binding domain comprises at least a part of the CDR-H3 or the complete CDR-H3 of murine monoclonal antibody A5B7, a pharmaceutical composition comprising the bispecific single chain antibody, and methods for the treatment of an epithelial tumor in a human with the pharmaceutical compositions containing the bispecific single chain antibody. Furthermore, processes for the production of the pharmaceutical compositions as well as medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CEA antigen are disclosed.
    Type: Grant
    Filed: December 21, 2006
    Date of Patent: March 12, 2013
    Assignee: Micromet AG
    Inventors: Ralf Lutterbüse, Petra Mayer, Evelyne Schaller, Doris Rau, Susanne Mangold, Peter Kufer, Alexander Murr, Tobias Raum, Monika Wissinger